ArticleFrontiers in neurology
Anti-CGRP monoclonal antibody therapy for migraine is not associated with early adverse bone effects: a prospective, observational, controlled, cohort study.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06035458 (Potential Osteocatabolic Effect Caused by Anti-CGRP mAbs in Migraine Patients Treated With Anti-CGRP mAbs - an Observational Pilot Project With Prospectively Collected Health Related Data), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Potential Osteocatabolic Effect Caused by Anti-CGRP mAbs in Migraine Patients Treated With Anti-CGRP mAbs - an Observational Pilot Project With Prospectively Collected Health Related Data
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Calcitonin gene-related peptide (CGRP) is a key mediator in migraine and a target of recent preventive therapies. Since CGRP is also expressed in bone and involved in skeletal regulation, concerns have been raised regarding potential bone effects of CGRP pathway inhibition. We report a prespecified 6-month analysis of a prospective, observational controlled, cohort study evaluating early bone outcomes during anti-CGRP monoclonal antibody (mAb) therapy. Methods: Adults with migraine initiating anti-CGRP mAb monotherapy (treated, Results: At baseline, BMD, TBS, CTX and P1NP were within the expected age-specific range in both groups. After 6 months of anti-CGRP mAb exposure all values remained within normal ranges and no clinically meaningful changes in BMD, TBS, CTX or P1NP were observed. In adjusted models, no significant group×time interactions were detected for BMD, CTX or P1NP (all Discussion: This prospective, observational, controlled, cohort study suggests that anti-CGRP mAb therapy is not associated with early adverse effects on bone density, structure, or turnover, while providing substantial migraine improvement. Ongoing follow-up will determine longer-term skeletal safety. Clinical trial registration: ClinicalTrials.gov, NCT06035458.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.